The Guillain-Barre Syndrome Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Guillain-Barre Syndrome Market?
The market size for Guillain-Barre Syndrome has seen robust growth recently. It is projected to increase from $0.60 billion in 2024 to $0.64 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 5.9%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Guillain-Barre Syndrome Industry?
The Guillain-Barre Syndrome global market is projected to grow to $0.79 billion by 2029, with a compound annual growth rate (CAGR) of 5.6%.
Download Your Free Sample of the 2025 Guillain-Barre Syndrome Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Guillain-Barre Syndrome Market?
The key drivers in the guillain-barre syndrome market are:
• Increasing prevalence of Guillain-Barre Syndrome
• Growing impact of climate change, which affects disease spread
• Increasing use and development of immunotherapies and drugs
• Advancements and increasing capabilities in diagnostics
Global Market Segmentation: Identifying Major Guillain-Barre Syndrome Industry Segments
The guillain-barre syndrome market covered in this report is segmented –
1) By Type: Acute Inflammatory Demyelinating Polyneuropathy (AIDP), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN), Other Types
2) By Therapeutics: Intravenous Immunoglobulin (IVIG), Plasma Exchange, Other Therapeutics
3) By Route Of Administration: Parenteral, Oral
4) By End User: Hospitals, Clinics, Diagnostic Centers, Other End Users
Subsegments:
1) By Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Classical AIDP, AIDP with Autonomic Involvement
2) By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Progressive CIDP, Relapsing-Remitting CIDP, Multifocal CIDP
3) By Miller Fisher Syndrome (MFS): Classical MFS, MFS With Ataxia, MFS With Ophthalmoplegia
4) By Acute Motor Axonal Neuropathy (AMAN): Classical AMAN, AMAN with Respiratory Involvement
5) By Other Types: Acute Sensory Ganglionopathy, Variants With Cranial Nerve Involvement, Bickerstaff Brainstem Encephalitis
Pre-order the 2025 Guillain-Barre Syndrome Global Market Report for Fast Delivery & Comprehensive Insights!
What are the emerging Trends Shaping the Future of the Guillain-Barre Syndrome Market?
The key trends in the guillain-barre syndrome market are:
• Enhanced diagnostic techniques for Guillain-Barre Syndrome are emerging as a significant trend.
• Development of immunoglobulin therapies is shaping the future of this market.
• Improved methods of plasmapheresis and exploration of gene therapy are also upcoming trends.
• Increased focus on early intervention, novel biomarkers for prognosis and expanded clinical trials for innovative treatments forecast the future developments in the market.
Who Are the Top Competitors & Leading Players in the Guillain-Barre Syndrome Market?
Major players in the guillain-barre syndrome market are:
• Pfizer Inc.
• Roche AG
• Thermo Fisher Scientific Inc.
• AstraZeneca PLC
• GSK plc
• Takeda Pharmaceutical Company Limited
• Merck & Co. Inc.
• Baxter International Inc.
• Biogen Inc.
• Horizon Therapeutics
• Octapharma AG
• Kedrion S.p.A.
• Annexon Inc.
• Immunovant Inc.
• CSL Behring LLC
• Hansa Biopharma AB
• NeuLine Health Inc.
• Ridge Diagnostics Inc.
• Deymed Diagnostic LLC
• VYVGART Hytrulo
Regional Dominance: Which Area Leads the Global Template Market?
North America was the largest region in the guillain-barre syndrome market in 2024
